BioVie Inc. announced on August 7, 2025, the pricing of an underwritten public offering of 6,000,000 units, each consisting of one share of common stock and one warrant. The units are being sold at a price of $2.00 per unit.
The warrants included in the units will be immediately exercisable at an exercise price of $2.50 per share and will expire five years from the date of issuance. These warrants have been approved for listing on the Nasdaq Capital Market under the symbol 'BIVIW' and are expected to commence trading on August 8, 2025.
The company expects to receive approximately $12 million in gross proceeds from this offering, before deducting underwriting discounts and commissions and other estimated expenses. The proceeds are intended for working capital and general corporate purposes, with the offering expected to close on August 11, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.